Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cerilliant
Merck
Chubb
QuintilesIMS
Teva
Boehringer Ingelheim
Queensland Health
Moodys

Generated: December 9, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENTECAVIR

« Back to Dashboard

Clinical Trials for Entecavir

Trial ID Title Status Sponsor Phase Summary
NCT00035633 A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen Completed Bristol-Myers Squibb Phase 3 The purpose of this clinical research study is to assess the safety effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen positive.
NCT00035789 A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen Completed Bristol-Myers Squibb Phase 3 The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen negative.
NCT00036608 A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine Completed Bristol-Myers Squibb Phase 3 The purpose of this clinical research study is to assess the safety and effectiveness of switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.
NCT00051038 Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients Completed Bristol-Myers Squibb Phase 2/Phase 3 The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis B infection who are co-infected with HIV.
NCT00065507 Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation Completed Bristol-Myers Squibb Phase 3 This is a phase IIIb comparative study of entecavir 1.0 mg once daily (QD) vs. adefovir 10 mg QD in patients who have chronic hepatitis B infection and hepatic decompensation. The patients are treated for 96 weeks after the last subject is randomized.
NCT00096785 Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection Completed Bristol-Myers Squibb Phase 3 The purpose of this study is to evaluate antiviral activity and efficacy of entecavir (ETV) compared to adefovir in adults with chronic hepatitis B who have not been treated yet with an antiviral medicine.
NCT00096811 Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program No longer available Bristol-Myers Squibb N/A The purpose of this clinical research study is to provide entecavir to subjects with chronic Hepatitis B infection who have failed or who have demonstrated intolerance of marketed therapies or for those in whom use of these agents is contraindicated and that have no other available treatment options.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Entecavir

Condition Name

Condition Name for Entecavir
Intervention Trials
Chronic Hepatitis B 65
Hepatitis B, Chronic 34
Hepatitis B 33
Hepatitis B Virus 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Entecavir
Intervention Trials
Hepatitis B 159
Hepatitis 146
Hepatitis B, Chronic 123
Hepatitis A 122
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Entecavir

Trials by Country

Trials by Country for Entecavir
Location Trials
United States 212
China 202
Korea, Republic of 57
Japan 35
Brazil 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Entecavir
Location Trials
California 21
New York 17
Maryland 15
Texas 14
Florida 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Entecavir

Clinical Trial Phase

Clinical Trial Phase for Entecavir
Clinical Trial Phase Trials
Phase 4 78
Phase 3 25
Phase 2/Phase 3 3
[disabled in preview] 64
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Entecavir
Clinical Trial Phase Trials
Completed 55
Recruiting 40
Unknown status 29
[disabled in preview] 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Entecavir

Sponsor Name

Sponsor Name for Entecavir
Sponsor Trials
Bristol-Myers Squibb 32
Tongji Hospital 8
Shanghai Zhongshan Hospital 7
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Entecavir
Sponsor Trials
Other 287
Industry 88
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cipla
Medtronic
Express Scripts
Julphar
Cerilliant
Fuji
Covington
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.